Advanced Ca-doped MOF nanocarriers for Co-delivery of Doxorubicin/pCRISPR

This is the authors' abstract. We don't add key points for this paper.

Cancer treatment often requires a multimodal approach, such as combining chemotherapy and gene therapy. However, challenges such as low therapeutic efficacy and off-target effects hinder the effectiveness of these treatments. In this study, the use of calcium-doped metal-organic frameworks Cu2(BDC)2(DABCO) as a nanocarrier platform for the co-delivery of doxorubicin (DOX) and plasmid CRISPR (pCRISPR) proposed to enhance anticancer efficiency. We demonstrated that Ca-doped MOF nanocarriers significantly improved the uptake of DOX and pCRISPR by in cancer cells. The co-delivery of DOX and pCRISPR with Ca-doped MOF nanocarriers resulted in a significant rise in cell death and decreased targeted gene expression.